Auris Medical Holding AG, a clinical-stage biopharmaceutical company, focuses on the development of novel products for the treatment of inner ear disorders. Its product candidates include AM-101, which is in phase III clinical development for the treatment of acute inner ear tinnitus; and AM-111 that is in phase III clinical development for the treatment of acute inner ear hearing loss. The company is also developing AM-125 for the treatment of vestibular disorders; and other pre-clinical stage products comprising AM-102 and AM-123. It has a collaboration and license agreement with Xigen S.A. to develop, manufacture, and commercialize pharmaceutical products, as well as drug delivery devices and formulations for local administration of therapeutic substances to the inner ear for the treatment of ear disorders. The company was formerly known as Auris Medical AG and changed its name to Auris Medical Holding AG in April 2014. Auris Medical Holding AG was founded in 1998 and is headquartered in Zug, Switzerland.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone41-41-729-7194
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date5/21/2019 (Estimated)
OptionableNot Optionable
Auris Medical (NASDAQ:EARS) Frequently Asked Questions
What is Auris Medical's stock symbol?
Auris Medical trades on the NASDAQ under the ticker symbol "EARS."
How were Auris Medical's earnings last quarter?
Auris Medical Holding AG (NASDAQ:EARS) announced its quarterly earnings results on Thursday, March, 14th. The biotechnology company reported ($0.12) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.11) by $0.01. View Auris Medical's Earnings History.
When is Auris Medical's next earnings date?
What price target have analysts set for EARS?
2 Wall Street analysts have issued 1 year price targets for Auris Medical's stock. Their predictions range from $2.50 to $5.00. On average, they anticipate Auris Medical's share price to reach $3.75 in the next twelve months. This suggests a possible upside of 913.5% from the stock's current price. View Analyst Price Targets for Auris Medical.
What is the consensus analysts' recommendation for Auris Medical?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Auris Medical in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Auris Medical.
Has Auris Medical been receiving favorable news coverage?
News coverage about EARS stock has been trending somewhat positive recently, according to InfoTrie Sentiment. The research group identifies positive and negative media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Auris Medical earned a media sentiment score of 1.7 on InfoTrie's scale. They also gave news coverage about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the near term.
Are investors shorting Auris Medical?
Auris Medical saw a decrease in short interest in the month of February. As of February 28th, there was short interest totalling 878,047 shares, a decrease of 27.2% from the February 15th total of 1,205,624 shares. Based on an average daily volume of 894,791 shares, the days-to-cover ratio is presently 1.0 days. Approximately 3.6% of the shares of the company are short sold. View Auris Medical's Current Options Chain.
Who are some of Auris Medical's key competitors?
Some companies that are related to Auris Medical include CTI BioPharma (CTIC), IntelGenx Technologies (IGXT), Avenue Therapeutics (ATXI), Innovate Biopharmaceuticals (INNT), Zosano Pharma (ZSAN), Oramed Pharmaceuticals (ORMP), Forward Pharma A/S (FWP), Scpharmaceuticals (SCPH), Sienna Biopharmaceuticals (SNNA), Arcturus Therapeutics (ARCT), Neurotrope (NTRP), Vistagen Therapeutics (VTGN), KemPharm (KMPH), Generex Biotechnology (GNBT) and Relmada Therapeutics (RLMD).
What other stocks do shareholders of Auris Medical own?
Who are Auris Medical's key executives?
Auris Medical's management team includes the folowing people:
- Dr. Thomas Meyer, Founder, Chairman, CEO & MD (Age 51)
- Mr. Hernan Levett CPA, Chief Financial Officer (Age 43)
- Colleen A. DeVries, SVP of Cogency Global Inc.
How do I buy shares of Auris Medical?
Shares of EARS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Auris Medical's stock price today?
One share of EARS stock can currently be purchased for approximately $0.37.
How big of a company is Auris Medical?
Auris Medical has a market capitalization of $13.88 million. The biotechnology company earns $-11,750,000.00 in net income (profit) each year or ($0.74) on an earnings per share basis.
What is Auris Medical's official website?
How can I contact Auris Medical?
Auris Medical's mailing address is BAHNHOFSTRASSE 21, ZUG V8, 6300. The biotechnology company can be reached via phone at 41-41-729-7194 or via email at [email protected]
MarketBeat Community Rating for Auris Medical (NASDAQ EARS)
MarketBeat's community ratings are surveys of what our community members think about Auris Medical and other stocks. Vote "Outperform" if you believe EARS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EARS will underperform the S&P 500 over the long term. You may vote once every thirty days.
